|
|
Post by goodby1 on Jun 27, 2014 12:27:18 GMT -5
|
|
|
|
Post by savzak on Jun 27, 2014 12:40:54 GMT -5
"Rosenstock added that, "If we had less sulfonylurea," "it is highly conceivable that we would have had much, much less hypoglycemia.""
Sulfonylurea agents (or oral hypoglycemic agents) are one of six types of diabetes pills currently available to treat type 2 diabetes.
There are many different Sulfonylurea agents:
Diabeta® (glyburide)
Diabinese® (chlorpropamide)
Micronase® (glyburide)
Orinase® (tolbutamide)
Glynase Prestab® (micronized glyburide)
Tolinase® (tolazamide)
Glucotro1® (glipizide)
Glucotrol XL® (glipizide extended release)
Amaryl® (glimepiride)
|
|
|
|
Post by thekindaguyiyam on Jun 27, 2014 12:43:50 GMT -5
this: "Even if the FDA approves Technosphere Insulin Inhalation Powder (TI) in the US, will it get recommended?" This directly states that Afrezza is the first Technosphere drug. Now people will wonder a little more perhaps about the influence of an alternative and more effective delivery system call Technospere. Once accepted all of those patents will be a faster acting delivery of medication; a shift in paradigm.
Thanks for the post!
|
|
|
|
Post by ezrasfund on Jun 27, 2014 12:49:27 GMT -5
Another view of the negative bias of the FDA statisticians comes across in the lower incidence of hypoglycemia observed in the Type 1 171 study. The FDA pointed out that the Afrezza arm of the study was titrated to a higher dose of basal insulin, so they asked if that gave Afrezza an unfair advantage in the HbA1c. The answer is that even with a lower dose of basal insulin injected parandial insulin causes more hypoglycemia than Afrezza.
|
|
|
|
Post by babaoriley on Jun 27, 2014 13:02:59 GMT -5
Gosh, this Technosphere Insulin stuff is fantastic! Who the heck makes this stuff? LOL!
I loved the following: "This (cough) did not cause a large dropout; there was a small decrement in pulmonary function that was reversible," Bode said. "TI had significantly less hypoglycemia no matter how you looked at it."
|
|
